US20050055091A1 - Process for making silicone intraocular lens with blue light absorption properties - Google Patents
Process for making silicone intraocular lens with blue light absorption properties Download PDFInfo
- Publication number
- US20050055091A1 US20050055091A1 US10/657,781 US65778103A US2005055091A1 US 20050055091 A1 US20050055091 A1 US 20050055091A1 US 65778103 A US65778103 A US 65778103A US 2005055091 A1 US2005055091 A1 US 2005055091A1
- Authority
- US
- United States
- Prior art keywords
- medical device
- intraocular lens
- reactive
- group
- reactive dye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- HPDXKRDQARPHRU-UHFFFAOYSA-N C=C.C[SiH3].[H][SiH3] Chemical compound C=C.C[SiH3].[H][SiH3] HPDXKRDQARPHRU-UHFFFAOYSA-N 0.000 description 1
- PQBBDXNHTMJBLZ-UHFFFAOYSA-N C=CC/[C-]=O/Cl.C=CCCCN=NC1=CC=CC=C1.OCCN(CCO)CN=NC1=CC=CC=C1 Chemical compound C=CC/[C-]=O/Cl.C=CCCCN=NC1=CC=CC=C1.OCCN(CCO)CN=NC1=CC=CC=C1 PQBBDXNHTMJBLZ-UHFFFAOYSA-N 0.000 description 1
- WGXCVSDZVHRCRZ-UHFFFAOYSA-N C=CCC.C=CCCN=NC1=CC=CC=C1.OCCN(CCO)CN=NC1=CC=CC=C1 Chemical compound C=CCC.C=CCCN=NC1=CC=CC=C1.OCCN(CCO)CN=NC1=CC=CC=C1 WGXCVSDZVHRCRZ-UHFFFAOYSA-N 0.000 description 1
- LCOOBIOTZJNTKU-UHFFFAOYSA-N [H]N(CCc1ccc(O)c(N=Nc2ccccc2C)c1)C(=O)CC=C Chemical compound [H]N(CCc1ccc(O)c(N=Nc2ccccc2C)c1)C(=O)CC=C LCOOBIOTZJNTKU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
- A61F2/16—Intraocular lenses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
- G02B1/04—Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
- G02B1/04—Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
- G02B1/041—Lenses
- G02B1/043—Contact lenses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/442—Colorants, dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
Definitions
- the present invention relates to a process for making silicone intraocular lenses with blue light absorption properties. More particularly, the present invention relates to a process for reacting a silicone intraocular lens with an ethyleneically unsaturated yellow dye to produce an intraocular lens capable of blocking blue light.
- intraocular lens Since the 1940's optical devices in the form of intraocular lens (IOL) implants have been utilized as replacements for diseased or damaged natural ocular lenses. In most cases, an intraocular lens is implanted within an eye at the time of surgically removing the diseased or damaged natural lens, such as for example, in the case of cataracts. For decades, the preferred material for fabricating such intraocular lens implants was poly(methyl methacrylate), which is a rigid, glassy polymer.
- Softer, more flexible IOL implants have gained in popularity in more recent years due to their ability to be compressed, folded, rolled or otherwise deformed. Such softer IOL implants may be deformed prior to insertion thereof through an incision in the cornea of an eye. Following insertion of the IOL in an eye, the IOL returns to its original pre-deformed shape due to the memory characteristics of the soft material. Softer, more flexible IOL implants as just described may be implanted into an eye through an incision that is much smaller, i.e., less than 4.0 mm, than that necessary for more rigid IOLs, i.e., 5.5 to 7.0 mm.
- a larger incision is necessary for more rigid IOL implants because the lens must be inserted through an incision in the cornea slightly larger than the diameter of the inflexible IOL optic portion. Accordingly, more rigid IOL implants have become less popular in the market since larger incisions have been found to be associated with an increased incidence of postoperative complications, such as induced astigmatism.
- Mazzocco U.S. Pat. No. 4,573,998 discloses a deformable intraocular lens that can be rolled, folded or stretched to fit through a relatively small incision. The deformable lens is inserted while it is held in its distorted configuration, then released inside the chamber of the eye, whereupon the elastic property of the lens causes it to resume its molded shape.
- suitable materials for the deformable lens Mazzocco discloses polyurethane elastomers, silicone elastomers, hydrogel polymer compounds, organic or synthetic gel compounds and combinations thereof.
- Soft, foldable, high refractive index, silicone intraocular lenses (IOLs) capable of absorbing blue light are prepared in accordance with the present invention through a coating process using a reactive yellow dye solution having blue light blocking properties.
- the blue light absorbing IOLs produced in accordance with the present invention protect an eye's retina from potentially damaging blue light and thereby possibly providing protection from macular degeneration.
- Blue light blocking silicone IOLs of the present invention are produced by exposing a semi-finished silicone IOL to an ethyleneically unsaturated yellow dye-containing solution and allowing the same to undergo a hydrosilation reaction. Such production process yields silicone IOLs with blue light absorbing properties. By absorbing blue light, the IOL serves to block blue light from reaching and potentially damaging the retina of an eye implanted with the IOL. Silicone IOLs so produced are transparent, relatively high in elongation and relatively high in refractive index.
- Another object of the present invention is to provide a process for the production of silicone IOLs having relatively high refractive indices and good clarity.
- Another object of the present invention is to provide a process for the production of silicone IOLs that are flexible.
- Still another object of the present invention is to provide biocompatible silicone IOLs capable of absorbing blue light.
- the present invention relates to a novel process for the production of high refractive index silicone IOLs capable of absorbing blue light and thereby blocking blue light from reaching the retina of an eye implanted with the IOL.
- Silicone IOLs of the present invention are produced by allowing a semi-finished silicone IOL to react with an ethyleneically unsaturated dye through a hydrosilation reaction.
- the subject process for treating silicone IOLs is relatively simple and produces biocompatible silicone IOLs capable of absorbing blue light.
- a “semi-finished” silicone IOL for purposes of the present invention is a silicone IOL having free hydrosilyl groups.
- a semi-finished silicone IOL in a weak solvent, such as for example but not limited to methylene chloride, containing a one or more reactive dyes, such as a reactive yellow dye, and one or more platinum catalysts, followed by thermal treatment of the IOL in an oven at a low temperature, preferably less than approximately 100° C. for a relatively short period of time, preferably less than several hours and more preferably less than approximately 30 minutes, a quantitative amount of dye can be incorporated into or coat the IOL.
- a weak solvent such as for example but not limited to methylene chloride
- a one or more reactive dyes such as a reactive yellow dye
- platinum catalysts platinum catalysts or catalyst systems suitable for the hydrosilation reaction of the present invention, depending on the reaction temperature and kinetics desired.
- platinum (3 to 3.5%)-divinyltetramethyldisiloxane complex is suitable for use in a room temperature reaction.
- Platinum (3 to 3.5%)-cyclovinylmethylsiloxane complex is suitable for use in a reaction at a moderate temperature of 50 to 100° C.
- the reaction kinetics can be regulated through the concentration of the catalyst and through the addition of various amounts of one or more inhibitors.
- Suitable inhibitors include for example but are not limited to 1,3-divinyltetramethyldisiloxane and 1,3,5,7-tetramethyl-1,3,5,7-tetravinyl cyclosiloxane. Such inhibitors may be present in the catalyst complex.
- Si —H represents the free hydrosilyl groups of a “semi-finished” silicone IOL
- H 2 C ⁇ CR 1 R 2 represents a reactive yellow dye.
- R 1 can be H or CH 3 and R 2 is a group containing other functional groups as well as functional groups responsible for yellow color.
- the reactive yellow dye can have for example, but is not limited to the following ethylenically unsaturated groups: vinyl, allyl, acrylate, methacrylate, acrylamide, methacrylamide, fumarate, maleate, itaconate, styrene, nitrile and the like.
- the reactive yellow dye can penetrate into the polymer matrix of the lens body, as well as, partially or completely coat the lens surface.
- Reactive dyes useful in the manufacture of flexible, high refractive index silicone IOLs capable of absorbing blue light may be prepared through a process of multiple chemical reaction steps.
- This process includes a step for forming a blue light absorbing functional group, i.e., a dye, such as for example but not limited to a diazo coupling for azo dye formation.
- the process also includes a step to incorporate the compound with a dye functional group and a reagent that is ethylenically unsaturated.
- a reactive azo yellow dye having two ethylenically unsaturated groups can be prepared by reacting a yellow dye having two alcohol groups with an acid chloride or an isocyanate having an ethylenically unsaturated group.
- a reactive yellow dye with one ethylenically unsaturated group useful in accordance with the present invention such as for example but not limited to N-2-[3′-(2′′-methylphenylazo)-4′-hydroxyphenyl]ethyl vinylacetamide, represented below in Formula 1, can be prepared by first reacting vinylacetyl chloride with 4-aminoethylphenol to give 4-vinylacetamidoethyl phenol, which is then coupled with the diazonium salt of toluidine as described in more detail below in Example 4.
- N,N-bis-(2-hydroxyethyl)-(4-phenylazo) aniline is accomplished by coupling the diazonium salt of aniline with N-phenyl diethanolamine.
- a detailed procedure is also described in D. L. Jinkerson, U.S. Pat. No. 5,470,932, incorporated herein in its entirety by reference.
- the contents are chilled with an ice bath.
- 4.18 g (0.04 mole) of vinylacetyl chloride is added into the flask over a period of 30 minutes.
- the ice bath is then removed and the contents are continuously stirred overnight.
- the mixture is then filtered and then condensed using a rotavapor.
- HPLC analysis indicates only one major product.
- the product is then passed through silica gel chromatography to give a final purified product with a yield of at least 80 percent.
- the product is identified by NMR and Mass Spectroscopy.
- N-2-[3′-(2′′-methylphenylazo)-4′-hydroxyphenyl]ethyl vinylacetamide can be made in two steps.
- the first step is the formation of 4-vinylacetamidoethyl phenol.
- the second step is the coupling of azonium salt of toluidine with the phenol to give the product.
- Step 1 Synthesis of 4-vinylacetamidoethyl phenol.
- Step 2 Coupling of product from Step 1 with toluidine diazonium salt.
- Model LI61 U lenses are silicone IOLs derived from components consisting of a vinyl terminated polydimethyl-co-diphenyl siloxane, silicon-based reinforcing resins with vinyl groups, and an oligomer with multi hydrosilane units. Model LI61 U silicone lenses have excess free hydrosilane groups after curing.
- UV UV
- visible absorption spectroscopy of coated lenses before and after processing.
- Conditions, which give about or less than 50% transmittance and maintenance of lens power/cosmetics are chosen for further coating studies, followed by optimization of conditions.
- Suitable catalysts for use in the process of the present invention include but are not limited to platinum (3-3.5%)-divinyltetramethyldisiloxane complex and platinum (3-3.5%)-cyclovinylmethylsiloxane complex.
- the silicone IOLs produced as described herein have the flexibility required to allow the same to be folded or deformed for insertion into an eye through the smallest possible surgical incision, i.e., 3.5 mm or smaller. It is unexpected that the subject silicone IOLs described herein could possess the ideal physical properties disclosed herein. The ideal physical properties of the subject silicone IOLs are unexpected because changes in mechanical properties such as modulus, percent elongation and tear strength can occur upon addition of the reactive dye functional groups.
- Silicone IOLs treated using the process of the present invention can be of any design capable of being rolled or folded for implantation through a relatively small surgical incision, i.e., 3.5 mm or less.
- Such IOLs may be manufactured to have an optic portion and haptic portions made of the same or differing materials. Once the material(s) are selected, the same may be cast in molds of the desired shape, cured and removed from the molds. After such molding, the IOLs are treated in accordance with the process of the present invention and then cleaned, polished, packaged and sterilized by customary methods known to those skilled in the art.
- the process of the present invention is also suitable for use in the production of other medical or ophthalmic devices such as contact lenses, keratoprostheses, capsular bag extension rings, corneal inlays, corneal rings and like devices.
- Silicone IOLs manufactured using the process of the present invention are used as customary in the field of ophthalmology.
- a surgical cataract procedure an incision is placed in the cornea of an eye. Through the corneal incision the cataractous natural lens of the eye is removed (aphakic application) and an IOL is inserted into the anterior chamber, posterior chamber or lens capsule of the eye prior to closing the incision.
- the subject ophthalmic devices may likewise be used in accordance with other surgical procedures known to those skilled in the field of ophthalmology.
Abstract
A process for producing silicone intraocular lenses (IOLs) capable of absorbing blue light. Intraocular lenses so produced block blue light from reaching the retina of an eye implanted with the IOL. By blocking blue light from reaching the retina, the IOL thereby prevents potential damage to the retina.
Description
- The present invention relates to a process for making silicone intraocular lenses with blue light absorption properties. More particularly, the present invention relates to a process for reacting a silicone intraocular lens with an ethyleneically unsaturated yellow dye to produce an intraocular lens capable of blocking blue light.
- Since the 1940's optical devices in the form of intraocular lens (IOL) implants have been utilized as replacements for diseased or damaged natural ocular lenses. In most cases, an intraocular lens is implanted within an eye at the time of surgically removing the diseased or damaged natural lens, such as for example, in the case of cataracts. For decades, the preferred material for fabricating such intraocular lens implants was poly(methyl methacrylate), which is a rigid, glassy polymer.
- Softer, more flexible IOL implants have gained in popularity in more recent years due to their ability to be compressed, folded, rolled or otherwise deformed. Such softer IOL implants may be deformed prior to insertion thereof through an incision in the cornea of an eye. Following insertion of the IOL in an eye, the IOL returns to its original pre-deformed shape due to the memory characteristics of the soft material. Softer, more flexible IOL implants as just described may be implanted into an eye through an incision that is much smaller, i.e., less than 4.0 mm, than that necessary for more rigid IOLs, i.e., 5.5 to 7.0 mm. A larger incision is necessary for more rigid IOL implants because the lens must be inserted through an incision in the cornea slightly larger than the diameter of the inflexible IOL optic portion. Accordingly, more rigid IOL implants have become less popular in the market since larger incisions have been found to be associated with an increased incidence of postoperative complications, such as induced astigmatism.
- With recent advances in small-incision cataract surgery, increased emphasis has been placed on developing soft, foldable materials suitable for use in artificial IOL implants. Mazzocco, U.S. Pat. No. 4,573,998, discloses a deformable intraocular lens that can be rolled, folded or stretched to fit through a relatively small incision. The deformable lens is inserted while it is held in its distorted configuration, then released inside the chamber of the eye, whereupon the elastic property of the lens causes it to resume its molded shape. As suitable materials for the deformable lens, Mazzocco discloses polyurethane elastomers, silicone elastomers, hydrogel polymer compounds, organic or synthetic gel compounds and combinations thereof.
- In recent years, blue light (400-500 nm) has been recognized as being potentially hazardous to the retina. Accordingly, yellow dyes to block blue light have been used in foldable intraocular lenses, in conjunction with ultraviolet light absorbers, to avoid potential damaging effects. Freeman et al., U.S. Pat. No. 6,353,069, disclose high refractive index copolymers comprising two or more acrylate and/or methacrylate monomers with aromatic groups. Ophthalmic devices made of the copolymers may also include colored dyes, such as the yellow dyes disclosed in U.S. Pat. No. 5,470,932. Such materials exhibit sufficient strength to allow devices made of them, such as intraocular lenses, to be folded or manipulated without fracturing.
- Because of shortcomings in the properties of many soft, flexible materials used in the manufacture of ophthalmic devices, such as the formation of water vacuoles or “glistenings”, and low refractive index, which requires a lens to be relatively thick in order to provide a lens of proper refractive power, new materials and methods of manufacturing of ophthalmic devices are needed.
- Soft, foldable, high refractive index, silicone intraocular lenses (IOLs) capable of absorbing blue light are prepared in accordance with the present invention through a coating process using a reactive yellow dye solution having blue light blocking properties. The blue light absorbing IOLs produced in accordance with the present invention protect an eye's retina from potentially damaging blue light and thereby possibly providing protection from macular degeneration.
- Blue light blocking silicone IOLs of the present invention are produced by exposing a semi-finished silicone IOL to an ethyleneically unsaturated yellow dye-containing solution and allowing the same to undergo a hydrosilation reaction. Such production process yields silicone IOLs with blue light absorbing properties. By absorbing blue light, the IOL serves to block blue light from reaching and potentially damaging the retina of an eye implanted with the IOL. Silicone IOLs so produced are transparent, relatively high in elongation and relatively high in refractive index.
- Accordingly, it is an object of the present invention to provide a process for the production of silicone IOLs capable of absorbing blue light.
- Another object of the present invention is to provide a process for the production of silicone IOLs having relatively high refractive indices and good clarity.
- Another object of the present invention is to provide a process for the production of silicone IOLs that are flexible.
- Still another object of the present invention is to provide biocompatible silicone IOLs capable of absorbing blue light.
- These and other objectives and advantages of the present invention, some of which are specifically described and others that are not, will become apparent from the detailed description and claims that follow.
- The present invention relates to a novel process for the production of high refractive index silicone IOLs capable of absorbing blue light and thereby blocking blue light from reaching the retina of an eye implanted with the IOL. Silicone IOLs of the present invention are produced by allowing a semi-finished silicone IOL to react with an ethyleneically unsaturated dye through a hydrosilation reaction. The subject process for treating silicone IOLs is relatively simple and produces biocompatible silicone IOLs capable of absorbing blue light.
- A “semi-finished” silicone IOL for purposes of the present invention, is a silicone IOL having free hydrosilyl groups. By dipping a semi-finished silicone IOL in a weak solvent, such as for example but not limited to methylene chloride, containing a one or more reactive dyes, such as a reactive yellow dye, and one or more platinum catalysts, followed by thermal treatment of the IOL in an oven at a low temperature, preferably less than approximately 100° C. for a relatively short period of time, preferably less than several hours and more preferably less than approximately 30 minutes, a quantitative amount of dye can be incorporated into or coat the IOL. There are several platinum catalysts or catalyst systems suitable for the hydrosilation reaction of the present invention, depending on the reaction temperature and kinetics desired. For example, platinum (3 to 3.5%)-divinyltetramethyldisiloxane complex is suitable for use in a room temperature reaction. Platinum (3 to 3.5%)-cyclovinylmethylsiloxane complex is suitable for use in a reaction at a moderate temperature of 50 to 100° C. The reaction kinetics can be regulated through the concentration of the catalyst and through the addition of various amounts of one or more inhibitors. Suitable inhibitors include for example but are not limited to 1,3-divinyltetramethyldisiloxane and 1,3,5,7-tetramethyl-1,3,5,7-tetravinyl cyclosiloxane. Such inhibitors may be present in the catalyst complex. The chemical reaction that takes place as a result of this process is illustrated below in Reaction Scheme 1.
As depicted above in Reaction Scheme 1, Si —H represents the free hydrosilyl groups of a “semi-finished” silicone IOL, and H2C═CR1R2 represents a reactive yellow dye. Here, R1 can be H or CH3 and R2 is a group containing other functional groups as well as functional groups responsible for yellow color. The reactive yellow dye can have for example, but is not limited to the following ethylenically unsaturated groups: vinyl, allyl, acrylate, methacrylate, acrylamide, methacrylamide, fumarate, maleate, itaconate, styrene, nitrile and the like. Depending on the particular solvent and the concentration of reactive yellow dyes in the solvent, the reactive yellow dye can penetrate into the polymer matrix of the lens body, as well as, partially or completely coat the lens surface. - Reactive dyes useful in the manufacture of flexible, high refractive index silicone IOLs capable of absorbing blue light, may be prepared through a process of multiple chemical reaction steps. This process includes a step for forming a blue light absorbing functional group, i.e., a dye, such as for example but not limited to a diazo coupling for azo dye formation. The process also includes a step to incorporate the compound with a dye functional group and a reagent that is ethylenically unsaturated. For example, a reactive azo yellow dye having two ethylenically unsaturated groups can be prepared by reacting a yellow dye having two alcohol groups with an acid chloride or an isocyanate having an ethylenically unsaturated group. Such is depicted in Reaction Schemes 2 through 3 wherein a yellow dye, N,N-bis-(2-hydroxyethyl)-(4-phenylazo) aniline (Solvent Yellow 58), synthesized in accordance with the procedure of Example 1 below, is used as an example not intended to be limiting.
Here, “Ph” represents either C6H5 or C6H4, as appropriate.
Alternatively, a reactive yellow dye with one ethylenically unsaturated group useful in accordance with the present invention, such as for example but not limited to N-2-[3′-(2″-methylphenylazo)-4′-hydroxyphenyl]ethyl vinylacetamide, represented below in Formula 1,
can be prepared by first reacting vinylacetyl chloride with 4-aminoethylphenol to give 4-vinylacetamidoethyl phenol, which is then coupled with the diazonium salt of toluidine as described in more detail below in Example 4. - The process of the present invention for preparing flexible, high refractive index silicone IOLs with blue light absorption properties is described in still greater detail in the Examples provided below.
- The synthesis of N,N-bis-(2-hydroxyethyl)-(4-phenylazo) aniline is accomplished by coupling the diazonium salt of aniline with N-phenyl diethanolamine. A detailed procedure is also described in D. L. Jinkerson, U.S. Pat. No. 5,470,932, incorporated herein in its entirety by reference.
- A 1000-mL 3-neck, round bottom flask connected with a reflux condenser and a drying tube, is charged with 250 mL of methylene chloride, 5.7 grams (0.02 mole) of N,N-bis-(2-hydroxyethyl)-(4-phenylazo)aniline, 3.28 g of allyl isocyanate (0.04 mole) (Aldrich Chemical, Inc., Milwaukee, Wis.) and 0.014 g of dibutyltin dilaurate (Aldrich Chemical). The mixture is heated and refluxed overnight under vigorous stirring. The mixture is then checked with infrared spectroscopy and no residual isocyanate peak is found indicating the reaction is complete. The mixture is concentrated using a rotavapor. High performance liquid chromatography (HPLC) analysis indicates only one major product. The product is then passed through silica gel chromatography to give final purified product with a yield of at least 80 percent. The product is identified by nuclear magnetic resonance (NMR) and Mass Spectroscopy.
- A 1000-mL 3-neck, round bottom flask connected with a reflux condenser and a drying tube, is charged with 250 mL of methylene chloride, 5.7 grams (0.02 mole) of N,N-bis-(2-hydroxyethyl)-(4-phenylazo) aniline and 4.04 grams of triethylamine (0.04 mole). The contents are chilled with an ice bath. Through a dropping funnel, 4.18 g (0.04 mole) of vinylacetyl chloride is added into the flask over a period of 30 minutes. The ice bath is then removed and the contents are continuously stirred overnight. The mixture is then filtered and then condensed using a rotavapor. HPLC analysis indicates only one major product. The product is then passed through silica gel chromatography to give a final purified product with a yield of at least 80 percent. The product is identified by NMR and Mass Spectroscopy.
- N-2-[3′-(2″-methylphenylazo)-4′-hydroxyphenyl]ethyl vinylacetamide can be made in two steps. The first step is the formation of 4-vinylacetamidoethyl phenol. The second step is the coupling of azonium salt of toluidine with the phenol to give the product.
- Step 1. Synthesis of 4-vinylacetamidoethyl phenol.
- A 1000-mL 3-neck, round bottom flask connected with a reflux condenser and a drying tube, is charged with 250 mL of methylene chloride, 5.48 grams (0.04 mole) 4-aminoethylphenol and 4.04 grams (0.04 mole) triethylamine. The contents are chilled with an ice bath. Through a dropping funnel, 4.18 g (0.04 mole) of vinylacetyl chloride is added into the flask over a period of 30 minutes. The ice bath is then removed and the contents are continuously stirred overnight. The mixture is then filtered and then condensed using a rotavapor. High performance liquid chromatography (HPLC) analysis indicates only one major product. The product is then passed through silica gel chromatography to give a final purified product with a yield of at least 80 percent. The product is identified by NMR and Mass Spectroscopy.
- Step 2. Coupling of product from Step 1 with toluidine diazonium salt.
- The procedure is about the same as that described in D. L. Jinkerson, U.S. Pat. No. 5,470,932, Example 1, second half. The difference is that 4-Vinylacetamidoethyl phenol is used to replace the acrylamidoethyl phenol. The product is identified by NMR and Mass Spectroscopy.
- Solutions containing 0.1, 0.5, 1, 2 and 5 weight percent of the yellow dye of Example 4 in methylene chloride are prepared. To these solutions, platinum-cyclovinylmethylsiloxane complex (Gelest, Inc., Tullytown, Pa.) at 1% of the weight of the yellow dye is also added.
- Ten (10) freshly thermally cured SoFleX™ Model LI61 U (Bausch & Lomb, Incorporated, Rochester, N.Y.) lenses are submerged into each coating solution as described in Example 3 for 30, 60 and 120 minutes. The lenses are then removed from the coating solutions and air dried. The lenses are then placed in an oven at 80 to 90° C. for an hour. These lenses are then subjected to standard processing to get the final finished product.
- Model LI61 U lenses are silicone IOLs derived from components consisting of a vinyl terminated polydimethyl-co-diphenyl siloxane, silicon-based reinforcing resins with vinyl groups, and an oligomer with multi hydrosilane units. Model LI61 U silicone lenses have excess free hydrosilane groups after curing.
- Run ultraviolet (UV) and visible absorption spectroscopy of coated lenses before and after processing. Select the yellow dye concentration and residence time of lens in dye solution based on the visible light absorption of the process lenses between 400-500 nm. Conditions, which give about or less than 50% transmittance and maintenance of lens power/cosmetics are chosen for further coating studies, followed by optimization of conditions.
- Soft, foldable, relatively high refractive index of approximately 1.42 or greater, relatively high elongation of approximately 100 percent or greater, silicone IOLs with blue light absorption properties are synthesized through the process of the present invention. Suitable catalysts for use in the process of the present invention include but are not limited to platinum (3-3.5%)-divinyltetramethyldisiloxane complex and platinum (3-3.5%)-cyclovinylmethylsiloxane complex.
- The silicone IOLs produced as described herein have the flexibility required to allow the same to be folded or deformed for insertion into an eye through the smallest possible surgical incision, i.e., 3.5 mm or smaller. It is unexpected that the subject silicone IOLs described herein could possess the ideal physical properties disclosed herein. The ideal physical properties of the subject silicone IOLs are unexpected because changes in mechanical properties such as modulus, percent elongation and tear strength can occur upon addition of the reactive dye functional groups.
- Silicone IOLs treated using the process of the present invention can be of any design capable of being rolled or folded for implantation through a relatively small surgical incision, i.e., 3.5 mm or less. Such IOLs may be manufactured to have an optic portion and haptic portions made of the same or differing materials. Once the material(s) are selected, the same may be cast in molds of the desired shape, cured and removed from the molds. After such molding, the IOLs are treated in accordance with the process of the present invention and then cleaned, polished, packaged and sterilized by customary methods known to those skilled in the art.
- In addition to IOLs, the process of the present invention is also suitable for use in the production of other medical or ophthalmic devices such as contact lenses, keratoprostheses, capsular bag extension rings, corneal inlays, corneal rings and like devices.
- Silicone IOLs manufactured using the process of the present invention are used as customary in the field of ophthalmology. For example, in a surgical cataract procedure, an incision is placed in the cornea of an eye. Through the corneal incision the cataractous natural lens of the eye is removed (aphakic application) and an IOL is inserted into the anterior chamber, posterior chamber or lens capsule of the eye prior to closing the incision. However, the subject ophthalmic devices may likewise be used in accordance with other surgical procedures known to those skilled in the field of ophthalmology.
- While there is shown and described herein a process for producing silicone IOLs with blue light absorption properties, it will be manifest to those skilled in the art that various modifications may be made without departing from the spirit and scope of the underlying inventive concept and that the same is not limited to particular processes and structures herein shown and described except insofar as indicated by the scope of the appended claims.
Claims (47)
1. A method for treating medical devices comprising:
exposing a semi-finished silicone medical device to a solution containing one or more reactive dyes and one or more catalysts.
2. A method for treating medical devices to render said devices capable of absorbing blue light comprising:
exposing a semi-finished silicone medical device to a solution containing one or more reactive dyes and one or more catalysts.
3. The method of claim 1 or 2 wherein said medical device is selected from the group consisting of contact lenses, keratoprostheses, capsular bag extension rings, corneal inlays and corneal rings.
4. The method of claim 1 or 2 wherein said medical device is an intraocular lens.
5. The method of claim 1 or 2 wherein said reactive dyes having ethylenically unsaturated groups are selected from the group consisting of vinyl, allyl, acrylate, methacrylate, acrylamide, methacrylamide, fumarate, maleate, itaconate, styrene and nitrile.
6. The method of claim 1 or 2 wherein said catalysts are selected from the group consisting of platinum (3-3.5%)-divinyltetramethyldisiloxane complex and platinum (3-3.5%)-cyclovinylmethylsiloxane complex.
7. The method of claim 1 or 2 wherein said catalysts is a platinum catalyst.
8. The method of claim 1 or 2 wherein said medical device is thermally treated at a temperature less than about 100° C.
9. The method of claim 1 or 2 wherein said medical device is thermally treated at a temperature of about 80 to 90° C.
10. The method of claim 1 or 2 wherein said medical device is thermally treated for about 30 minutes.
11. The method of claim 1 or 2 wherein said medical device is thermally treated for a period of time less than several hours.
12. The method of claim 1 or 2 wherein said medical device is thermally treated for about 120 minutes or less.
13. A process for producing a medical device capable of absorbing blue light comprising:
exposing a medical device with free reactive groups to a solution containing one or more reactive dyes and one or more catalysts.
14. The process of claim 13 wherein said free reactive groups are free hydrosilyl groups.
15. The process of claim 13 wherein said medical device is selected from the group consisting of contact lenses, keratoprostheses, capsular bag extension rings, corneal inlays and corneal rings.
16. The process of claim 13 wherein said medical device is an intraocular lens.
17. The process of claim 13 wherein said reactive dyes having ethylenically unsaturated groups are selected from the group consisting of vinyl, allyl, acrylate, methacrylate, acrylamide, methacrylamide, fumarate, maleate, itaconate, styrene and nitrile.
18. The process of claim 13 wherein said catalysts are selected from the group consisting of platinum (3-3.5%)-divinyltetramethyldisiloxane complex and platinum (3-3.5%)-cyclovinylmethylsiloxane complex.
19. The process of claim 13 wherein said catalysts is a platinum catalyst.
20. The process of claim 13 wherein said medical device is thermally treated at a temperature less than about 100° C.
21. The process of claim 13 wherein said medical device is thermally treated at a temperature of about 80 to 90° C.
22. The process of claim 13 wherein said medical device is thermally treated for about 30 minutes.
23. The process of claim 13 wherein said medical device is thermally treated for a period of time less than several hours.
24. The process of claim 13 wherein said medical device is thermally treated for about 120 minutes or less.
25. A method of using the medical device produced through the method of claim 1 or 2 comprising:
implanting said medical device surgically within an eye.
26. A method of using the medical device produced through the process of claim 13 comprising:
implanting said medical device surgically within an eye.
27. The method of claim 1 or 2 wherein said catalyst includes one or more inhibitors.
28. The method of claim 1 or 2 wherein said catalyst includes one or more inhibitors selected from the group consisting of 1,3-divinyltetramethyldisiloxane and 1,3,5,7-tetramethyl-1,3,5,7-tetravinyl cyclosiloxane.
29. The process of claim 13 wherein said catalysts include one or more inhibitors.
30. The process of claim 13 wherein said catalysts include one or more inhibitors selected from the group consisting of 1,3-divinyltetramethyldisiloxane and 1,3,5,7-tetramethyl-1,3,5,7-tetravinyl cyclosiloxane.
31. A medical device comprising:
a medical device treated with at least one reactive dye so that said medical device has blue light absorption properties.
32. The medical device of claim 31 wherein said medical device is fabricated from semi-finished silicone.
33. The medical device of claim 31 wherein said at least one reactive dye having ethylenically unsaturated groups is selected from the group consisting of vinyl, allyl, acrylate, methacrylate, acrylamide, methacrylamide, fumarate, maleate, itaconate, styrene and nitrile.
34. The medical device of claim 31 wherein said reactive dye is a reactive yellow dye.
35. The medical device of claim 31 wherein said reactive dye has either one or two ethylenically unsaturated groups.
36. The medical device of claim 31 wherein said reactive dye is selected from the group consisting of N,N-bis-(2-allylcarbamatoethyl)-(4′-phenylazo)aniline and N,N-bis-(2-vinylacetoxyethyl)-(4′-phenylazo)aniline and N-2-[3′-(2″-methylphenylazo)-4′-hydroxyphenyl]ethyl vinylacetamide.
37. The medical device of claim 31 wherein said reactive dye undergoes a hydrosilation reaction with said medical device.
38. The medical device of claim 31 wherein said reactive dye penetrates into the polymer matrix of said medical device.
39. The medical device of claim 31 wherein said reactive dye partially or completely coats the surface of said medical device.
40. An intraocular lens comprising:
an intraocular lens treated with at least one reactive dye so that said intraocular lens has blue light absorption properties.
41. The intraocular lens of claim 40 wherein said medical device is fabricated from semi-finished silicone.
42. The intraocular lens of claim 40 wherein said reactive dye having ethylenically unsaturated groups is selected from the group consisting of vinyl, allyl, acrylate, methacrylate, acrylamide, methacrylamide, fumarate, maleate, itaconate, styrene and nitrile.
43. The intraocular lens of claim 40 wherein said reactive dye is a reactive yellow dye.
44. The intraocular lens of claim 40 wherein said reactive dye is selected from the group consisting of N,N-bis-(2-allylcarbamatoethyl)-(4′-phenylazo)aniline and N,N-bis-(2-vinylacetoxyethyl)-(4′-phenylazo)aniline and N-2-[3′-(2″-methylphenylazo)-4′-hydroxyphenyl]ethyl vinylacetamide.
45. The intraocular lens of claim 40 wherein said reactive dye undergoes a hydrosilation reaction with said medical device.
46. The intraocular lens of claim 40 wherein said reactive dye penetrates into the polymer matrix of said medical device.
47. The intraocular lens of claim 40 wherein said reactive dye partially or completely coats the surface of said medical device.
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/657,781 US20050055091A1 (en) | 2003-09-08 | 2003-09-08 | Process for making silicone intraocular lens with blue light absorption properties |
EP04781649A EP1663334A1 (en) | 2003-09-08 | 2004-08-19 | Intraocular lens with blue light absorption properties and process |
CA002536730A CA2536730A1 (en) | 2003-09-08 | 2004-08-19 | Intraocular lens with blue light absorption properties and process |
CNA2004800257104A CN1849146A (en) | 2003-09-08 | 2004-08-19 | Intraocular lens with blue light absorption properties and process |
JP2006525352A JP2007504855A (en) | 2003-09-08 | 2004-08-19 | Intraocular lens with blue light absorption characteristics and process |
KR1020067004688A KR20060076291A (en) | 2003-09-08 | 2004-08-19 | Intraocular lens with blue light absorption properties and process |
PCT/US2004/027006 WO2005025632A1 (en) | 2003-09-08 | 2004-08-19 | Intraocular lens with blue light absorption properties and process |
AU2004271948A AU2004271948A1 (en) | 2003-09-08 | 2004-08-19 | Intraocular lens with blue light absorption properties and process |
TW093127042A TW200518724A (en) | 2003-09-08 | 2004-09-07 | Process for making silicone intraocular lens with blue light absorption properties |
US11/235,441 US20060020338A1 (en) | 2003-09-08 | 2005-09-26 | Process for making silicone intraocular lens with blue light absorption properties |
US11/235,497 US7241312B2 (en) | 2003-09-08 | 2005-09-26 | Silicone intraocular lens with blue light absorption properties |
US11/235,454 US20060020340A1 (en) | 2003-09-08 | 2005-09-26 | Process for making silicone intraocular lens with blue light absorption properties |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/657,781 US20050055091A1 (en) | 2003-09-08 | 2003-09-08 | Process for making silicone intraocular lens with blue light absorption properties |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/235,497 Division US7241312B2 (en) | 2003-09-08 | 2005-09-26 | Silicone intraocular lens with blue light absorption properties |
US11/235,454 Division US20060020340A1 (en) | 2003-09-08 | 2005-09-26 | Process for making silicone intraocular lens with blue light absorption properties |
US11/235,441 Division US20060020338A1 (en) | 2003-09-08 | 2005-09-26 | Process for making silicone intraocular lens with blue light absorption properties |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050055091A1 true US20050055091A1 (en) | 2005-03-10 |
Family
ID=34226638
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/657,781 Abandoned US20050055091A1 (en) | 2003-09-08 | 2003-09-08 | Process for making silicone intraocular lens with blue light absorption properties |
US11/235,497 Expired - Fee Related US7241312B2 (en) | 2003-09-08 | 2005-09-26 | Silicone intraocular lens with blue light absorption properties |
US11/235,454 Abandoned US20060020340A1 (en) | 2003-09-08 | 2005-09-26 | Process for making silicone intraocular lens with blue light absorption properties |
US11/235,441 Abandoned US20060020338A1 (en) | 2003-09-08 | 2005-09-26 | Process for making silicone intraocular lens with blue light absorption properties |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/235,497 Expired - Fee Related US7241312B2 (en) | 2003-09-08 | 2005-09-26 | Silicone intraocular lens with blue light absorption properties |
US11/235,454 Abandoned US20060020340A1 (en) | 2003-09-08 | 2005-09-26 | Process for making silicone intraocular lens with blue light absorption properties |
US11/235,441 Abandoned US20060020338A1 (en) | 2003-09-08 | 2005-09-26 | Process for making silicone intraocular lens with blue light absorption properties |
Country Status (9)
Country | Link |
---|---|
US (4) | US20050055091A1 (en) |
EP (1) | EP1663334A1 (en) |
JP (1) | JP2007504855A (en) |
KR (1) | KR20060076291A (en) |
CN (1) | CN1849146A (en) |
AU (1) | AU2004271948A1 (en) |
CA (1) | CA2536730A1 (en) |
TW (1) | TW200518724A (en) |
WO (1) | WO2005025632A1 (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050283234A1 (en) * | 2004-06-18 | 2005-12-22 | Zhou Stephen Q | Photochromic intraocular lenses and methods of making the same |
US20060001184A1 (en) * | 2004-06-30 | 2006-01-05 | Phelan John C | Method for lathing silicone hydrogel lenses |
US20060004165A1 (en) * | 2004-06-30 | 2006-01-05 | Phelan John C | Silicone hydrogels with lathability at room temperature |
US20070037898A1 (en) * | 2005-08-10 | 2007-02-15 | Phelan John C | Silicone hydrogels |
US20070132949A1 (en) * | 2005-12-14 | 2007-06-14 | Phelan John C | Method for preparing silicone hydrogels |
US20070216861A1 (en) * | 2006-03-20 | 2007-09-20 | Andrew Ishak | Ophthalmic system combining ophthalmic components with blue light wavelength blocking and color-balancing functionalities |
US20080043200A1 (en) * | 2006-03-20 | 2008-02-21 | Ishak Andrew W | Color balanced ophthalmic system with selective light inhibition |
US20080090937A1 (en) * | 2006-10-13 | 2008-04-17 | Alcon Manufacturing Ltd. | Intraocular lenses with unique blue-violet cutoff and blue light transmission characteristics |
US20080186448A1 (en) * | 2006-03-20 | 2008-08-07 | High Performance Optics, Inc. | High performance selective light wavelength filtering providing improved contrast sensitivity |
US7556376B2 (en) | 2006-08-23 | 2009-07-07 | High Performance Optics, Inc. | System and method for selective light inhibition |
US20100113641A1 (en) * | 2008-11-04 | 2010-05-06 | Alcon, Inc. | Uv/visible light absorbers for ophthalmic lens materials |
EP2199834A1 (en) * | 2008-12-18 | 2010-06-23 | *Acri. Tec GmbH | Ophthalmological composition and ophthalmologic lens |
US8113651B2 (en) | 2006-03-20 | 2012-02-14 | High Performance Optics, Inc. | High performance corneal inlay |
US8403478B2 (en) | 2001-11-02 | 2013-03-26 | High Performance Optics, Inc. | Ophthalmic lens to preserve macular integrity |
US8882267B2 (en) | 2006-03-20 | 2014-11-11 | High Performance Optics, Inc. | High energy visible light filter systems with yellowness index values |
US9377569B2 (en) | 2006-03-20 | 2016-06-28 | High Performance Optics, Inc. | Photochromic ophthalmic systems that selectively filter specific blue light wavelengths |
US9545304B2 (en) | 2000-11-03 | 2017-01-17 | High Performance Optics, Inc. | Dual-filter ophthalmic lens to reduce risk of macular degeneration |
US9683102B2 (en) | 2014-05-05 | 2017-06-20 | Frontier Scientific, Inc. | Photo-stable and thermally-stable dye compounds for selective blue light filtered optic |
US9798163B2 (en) | 2013-05-05 | 2017-10-24 | High Performance Optics, Inc. | Selective wavelength filtering with reduced overall light transmission |
US9927635B2 (en) | 2006-03-20 | 2018-03-27 | High Performance Optics, Inc. | High performance selective light wavelength filtering providing improved contrast sensitivity |
US10935695B2 (en) | 2018-03-02 | 2021-03-02 | Johnson & Johnson Vision Care, Inc. | Polymerizable absorbers of UV and high energy visible light |
US11543683B2 (en) | 2019-08-30 | 2023-01-03 | Johnson & Johnson Vision Care, Inc. | Multifocal contact lens displaying improved vision attributes |
US11958824B2 (en) | 2020-06-11 | 2024-04-16 | Johnson & Johnson Vision Care, Inc. | Photostable mimics of macular pigment |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7217288B2 (en) | 2002-12-12 | 2007-05-15 | Powervision, Inc. | Accommodating intraocular lens having peripherally actuated deflectable surface and method |
US8328869B2 (en) | 2002-12-12 | 2012-12-11 | Powervision, Inc. | Accommodating intraocular lenses and methods of use |
US8361145B2 (en) | 2002-12-12 | 2013-01-29 | Powervision, Inc. | Accommodating intraocular lens system having circumferential haptic support and method |
US10835373B2 (en) | 2002-12-12 | 2020-11-17 | Alcon Inc. | Accommodating intraocular lenses and methods of use |
EP1599748A4 (en) | 2003-03-06 | 2007-10-24 | John H Shadduck | Adaptive optic lens and method of making |
CA2552122A1 (en) * | 2003-12-29 | 2005-07-21 | Advanced Medical Optics, Inc. | Intraocular lenses having a visible light-selective-transmissive-region |
AU2005242823B2 (en) | 2004-04-30 | 2011-04-14 | Johnson & Johnson Surgical Vision, Inc. | Ophthalmic devices having a highly selective violet light transmissive filter and related methods |
US9872763B2 (en) | 2004-10-22 | 2018-01-23 | Powervision, Inc. | Accommodating intraocular lenses |
BRPI0518030A (en) | 2004-11-22 | 2008-10-28 | Advanced Medical Optics Inc | copolymerizable methane and anthraquinone compounds and articles containing them |
ATE549649T1 (en) * | 2004-11-22 | 2012-03-15 | Abbott Medical Optics Inc | COPOLYMERIZABLE AZONE COMPOUNDS AND ITEMS CONTAINING THEM |
CN101321505B (en) | 2005-09-08 | 2015-12-02 | 卡尔豪恩视觉公司 | There is the novel adjustable optical elements strengthening ultraviolet protection |
CN101678149B (en) | 2007-02-21 | 2013-07-17 | 力景公司 | Polymeric materials suitable for ophthalmic devices and methods of manufacture |
US8668734B2 (en) | 2010-07-09 | 2014-03-11 | Powervision, Inc. | Intraocular lens delivery devices and methods of use |
JP5752415B2 (en) | 2007-07-23 | 2015-07-22 | パワーヴィジョン・インコーポレーテッド | Correction of the refractive power of the lens after implantation |
US8968396B2 (en) | 2007-07-23 | 2015-03-03 | Powervision, Inc. | Intraocular lens delivery systems and methods of use |
CA2696450C (en) | 2007-07-23 | 2016-02-16 | Terah Whiting Smiley | Lens delivery system |
US8314927B2 (en) | 2007-07-23 | 2012-11-20 | Powervision, Inc. | Systems and methods for testing intraocular lenses |
US9610155B2 (en) | 2008-07-23 | 2017-04-04 | Powervision, Inc. | Intraocular lens loading systems and methods of use |
EP2671541B1 (en) | 2007-07-23 | 2019-04-17 | PowerVision, Inc. | Accommodating intraocular lenses |
WO2009102454A1 (en) * | 2008-02-12 | 2009-08-20 | Aaren Scientific Inc. | Ophthalmic lens having a yellow dye light blocking component |
US10299913B2 (en) | 2009-01-09 | 2019-05-28 | Powervision, Inc. | Accommodating intraocular lenses and methods of use |
WO2011026068A2 (en) | 2009-08-31 | 2011-03-03 | Powervision, Inc. | Lens capsule size estimation |
KR101069110B1 (en) * | 2009-12-04 | 2011-09-30 | 손준홍 | Accommodative intraocular lens |
US8900298B2 (en) | 2010-02-23 | 2014-12-02 | Powervision, Inc. | Fluid for accommodating intraocular lenses |
US10433949B2 (en) | 2011-11-08 | 2019-10-08 | Powervision, Inc. | Accommodating intraocular lenses |
EP2967842B1 (en) | 2013-03-15 | 2020-11-04 | Alcon Inc. | Method of reconfiguring an intraocular lens for delivery to a delivery device |
KR101463956B1 (en) * | 2013-05-21 | 2014-11-26 | (주)소모옵티칼 | Lens For Blocking Blue Light |
US9085697B2 (en) | 2013-06-21 | 2015-07-21 | Benq Materials Corporation | Polymerizable yellow dye for manufacturing ophthalmic lens |
EP3370647B8 (en) | 2015-11-06 | 2021-06-30 | Alcon Inc. | Accommodating intraocular lenses and methods of manufacturing |
US20190285912A1 (en) * | 2018-03-13 | 2019-09-19 | Eyekeeper Global Inc. | Eye Protection Lens |
EP4041131A4 (en) | 2019-10-04 | 2023-11-15 | Alcon Inc. | Adjustable intraocular lenses and methods of post-operatively adjusting intraocular lenses |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4468229A (en) * | 1981-08-12 | 1984-08-28 | Ciba-Geigy Corporation | Tinted contact lenses and a method for their preparation with reactive dyes |
US5470932A (en) * | 1993-10-18 | 1995-11-28 | Alcon Laboratories, Inc. | Polymerizable yellow dyes and their use in opthalmic lenses |
US5891931A (en) * | 1997-08-07 | 1999-04-06 | Alcon Laboratories, Inc. | Method of preparing foldable high refractive index acrylic ophthalmic device materials |
US6015842A (en) * | 1997-08-07 | 2000-01-18 | Alcon Laboratories, Inc. | Method of preparing foldable hydrophilic ophthalmic device materials |
US6187042B1 (en) * | 1998-04-15 | 2001-02-13 | Alcon Laboratories, Inc. | Intraocular lens coating compositions |
US6353069B1 (en) * | 1998-04-15 | 2002-03-05 | Alcon Manufacturing, Ltd. | High refractive index ophthalmic device materials |
US20030078359A1 (en) * | 2001-09-14 | 2003-04-24 | Canon-Staar Co. Inc. | Dye for an intraocular lens and an intraocular lens using it |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69530488T2 (en) * | 1994-06-30 | 2004-04-01 | Minnesota Mining And Mfg. Co., St. Paul | DENTAL PRINT MATERIAL CONTAINING A DYE TO MAKE THE CURING VISIBLE |
JP4225612B2 (en) * | 1998-09-09 | 2009-02-18 | スター・ジャパン株式会社 | Ophthalmic lens material |
US6632905B2 (en) * | 1999-09-02 | 2003-10-14 | Alcon Universal Ltd. | Covalently-bound, hydrophilic coating compositions for surgical implants |
US6406739B1 (en) * | 2000-01-12 | 2002-06-18 | Alcon Universal Ltd. | Coating compositions and methods for reducing edge glare in implantable ophthalmic lenses |
EP1337284B1 (en) * | 2000-09-06 | 2007-12-05 | Alcon Inc. | Switchable tackiness coating compositions for ophthalmic implants |
-
2003
- 2003-09-08 US US10/657,781 patent/US20050055091A1/en not_active Abandoned
-
2004
- 2004-08-19 WO PCT/US2004/027006 patent/WO2005025632A1/en not_active Application Discontinuation
- 2004-08-19 EP EP04781649A patent/EP1663334A1/en not_active Withdrawn
- 2004-08-19 CN CNA2004800257104A patent/CN1849146A/en active Pending
- 2004-08-19 AU AU2004271948A patent/AU2004271948A1/en not_active Abandoned
- 2004-08-19 KR KR1020067004688A patent/KR20060076291A/en not_active Application Discontinuation
- 2004-08-19 CA CA002536730A patent/CA2536730A1/en not_active Abandoned
- 2004-08-19 JP JP2006525352A patent/JP2007504855A/en not_active Withdrawn
- 2004-09-07 TW TW093127042A patent/TW200518724A/en unknown
-
2005
- 2005-09-26 US US11/235,497 patent/US7241312B2/en not_active Expired - Fee Related
- 2005-09-26 US US11/235,454 patent/US20060020340A1/en not_active Abandoned
- 2005-09-26 US US11/235,441 patent/US20060020338A1/en not_active Abandoned
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4468229A (en) * | 1981-08-12 | 1984-08-28 | Ciba-Geigy Corporation | Tinted contact lenses and a method for their preparation with reactive dyes |
US5470932A (en) * | 1993-10-18 | 1995-11-28 | Alcon Laboratories, Inc. | Polymerizable yellow dyes and their use in opthalmic lenses |
US5528322A (en) * | 1993-10-18 | 1996-06-18 | Alcon Laboratories, Inc. | Polymerizable yellow dyes and their use in ophthalmic lenses |
US5543504A (en) * | 1993-10-18 | 1996-08-06 | Alcon Laboratories, Inc. | Polymerizable yellow dyes and their use in ophthalmic lenses |
US5662707A (en) * | 1993-10-18 | 1997-09-02 | Alcon Laboratories, Inc. | Polymerizable yellow dyes and their use in ophthalmic lenses |
US5891931A (en) * | 1997-08-07 | 1999-04-06 | Alcon Laboratories, Inc. | Method of preparing foldable high refractive index acrylic ophthalmic device materials |
US6015842A (en) * | 1997-08-07 | 2000-01-18 | Alcon Laboratories, Inc. | Method of preparing foldable hydrophilic ophthalmic device materials |
US6187042B1 (en) * | 1998-04-15 | 2001-02-13 | Alcon Laboratories, Inc. | Intraocular lens coating compositions |
US6353069B1 (en) * | 1998-04-15 | 2002-03-05 | Alcon Manufacturing, Ltd. | High refractive index ophthalmic device materials |
US20030078359A1 (en) * | 2001-09-14 | 2003-04-24 | Canon-Staar Co. Inc. | Dye for an intraocular lens and an intraocular lens using it |
US6878792B2 (en) * | 2001-09-14 | 2005-04-12 | Canon-Staar Co. Inc. | Dye for an intraocular lens and an intraocular lens using it |
US20050101690A1 (en) * | 2001-09-14 | 2005-05-12 | Canon-Staar Co. Inc. | Dye for an intraocular lens and an intraocular lens using it |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9545304B2 (en) | 2000-11-03 | 2017-01-17 | High Performance Optics, Inc. | Dual-filter ophthalmic lens to reduce risk of macular degeneration |
US8403478B2 (en) | 2001-11-02 | 2013-03-26 | High Performance Optics, Inc. | Ophthalmic lens to preserve macular integrity |
US8133274B2 (en) * | 2004-06-18 | 2012-03-13 | Medennium, Inc. | Photochromic intraocular lenses and methods of making the same |
US20050283234A1 (en) * | 2004-06-18 | 2005-12-22 | Zhou Stephen Q | Photochromic intraocular lenses and methods of making the same |
US9248614B2 (en) | 2004-06-30 | 2016-02-02 | Novartis Ag | Method for lathing silicone hydrogel lenses |
US20060004165A1 (en) * | 2004-06-30 | 2006-01-05 | Phelan John C | Silicone hydrogels with lathability at room temperature |
US20060001184A1 (en) * | 2004-06-30 | 2006-01-05 | Phelan John C | Method for lathing silicone hydrogel lenses |
US20070037898A1 (en) * | 2005-08-10 | 2007-02-15 | Phelan John C | Silicone hydrogels |
US7671156B2 (en) | 2005-08-10 | 2010-03-02 | Novartis Ag | Silicone hydrogels |
US20070132949A1 (en) * | 2005-12-14 | 2007-06-14 | Phelan John C | Method for preparing silicone hydrogels |
US7744785B2 (en) | 2005-12-14 | 2010-06-29 | Novartis Ag | Method for preparing silicone hydrogels |
US8501833B2 (en) | 2005-12-14 | 2013-08-06 | Novartis Ag | Method for preparing silicone hydrogels |
US20100227944A1 (en) * | 2005-12-14 | 2010-09-09 | John Christopher Phelan | Method for preparing silicone hydrogels |
US8360574B2 (en) | 2006-03-20 | 2013-01-29 | High Performance Optics, Inc. | High performance selective light wavelength filtering providing improved contrast sensitivity |
US20080043200A1 (en) * | 2006-03-20 | 2008-02-21 | Ishak Andrew W | Color balanced ophthalmic system with selective light inhibition |
US11774783B2 (en) | 2006-03-20 | 2023-10-03 | High Performance Optics, Inc. | High performance selective light wavelength filtering providing improved contrast sensitivity |
US9927635B2 (en) | 2006-03-20 | 2018-03-27 | High Performance Optics, Inc. | High performance selective light wavelength filtering providing improved contrast sensitivity |
US8113651B2 (en) | 2006-03-20 | 2012-02-14 | High Performance Optics, Inc. | High performance corneal inlay |
US10551637B2 (en) | 2006-03-20 | 2020-02-04 | High Performance Optics, Inc. | High performance selective light wavelength filtering providing improved contrast sensitivity |
US10610472B2 (en) | 2006-03-20 | 2020-04-07 | High Performance Optics, Inc. | High energy visible light filter systems with yellowness index values |
US7520608B2 (en) | 2006-03-20 | 2009-04-21 | High Performance Optics, Inc. | Color balanced ophthalmic system with selective light inhibition |
US9814658B2 (en) | 2006-03-20 | 2017-11-14 | High Performance Optics, Inc. | High energy visible light filter systems with yellowness index values |
US20080186448A1 (en) * | 2006-03-20 | 2008-08-07 | High Performance Optics, Inc. | High performance selective light wavelength filtering providing improved contrast sensitivity |
US20070216861A1 (en) * | 2006-03-20 | 2007-09-20 | Andrew Ishak | Ophthalmic system combining ophthalmic components with blue light wavelength blocking and color-balancing functionalities |
US8882267B2 (en) | 2006-03-20 | 2014-11-11 | High Performance Optics, Inc. | High energy visible light filter systems with yellowness index values |
US9063349B2 (en) | 2006-03-20 | 2015-06-23 | High Performance Optics, Inc. | High performance selective light wavelength filtering |
US11701315B2 (en) | 2006-03-20 | 2023-07-18 | High Performance Optics, Inc. | High energy visible light filter systems with yellowness index values |
US9377569B2 (en) | 2006-03-20 | 2016-06-28 | High Performance Optics, Inc. | Photochromic ophthalmic systems that selectively filter specific blue light wavelengths |
US7556376B2 (en) | 2006-08-23 | 2009-07-07 | High Performance Optics, Inc. | System and method for selective light inhibition |
US20080090937A1 (en) * | 2006-10-13 | 2008-04-17 | Alcon Manufacturing Ltd. | Intraocular lenses with unique blue-violet cutoff and blue light transmission characteristics |
US7691918B2 (en) | 2006-10-13 | 2010-04-06 | Alcon, Inc. | Intraocular lenses with unique blue-violet cutoff and blue light transmission characteristics |
US8232326B2 (en) | 2008-11-04 | 2012-07-31 | Novartis Ag | UV/visible light absorbers for ophthalmic lens materials |
US8153703B2 (en) | 2008-11-04 | 2012-04-10 | Novartis Ag | UV/visible light absorbers for ophthalmic lens materials |
US20100113641A1 (en) * | 2008-11-04 | 2010-05-06 | Alcon, Inc. | Uv/visible light absorbers for ophthalmic lens materials |
EP2199834A1 (en) * | 2008-12-18 | 2010-06-23 | *Acri. Tec GmbH | Ophthalmological composition and ophthalmologic lens |
US9798163B2 (en) | 2013-05-05 | 2017-10-24 | High Performance Optics, Inc. | Selective wavelength filtering with reduced overall light transmission |
US9683102B2 (en) | 2014-05-05 | 2017-06-20 | Frontier Scientific, Inc. | Photo-stable and thermally-stable dye compounds for selective blue light filtered optic |
US10935695B2 (en) | 2018-03-02 | 2021-03-02 | Johnson & Johnson Vision Care, Inc. | Polymerizable absorbers of UV and high energy visible light |
US11820899B2 (en) | 2018-03-02 | 2023-11-21 | Johnson & Johnson Vision Care, Inc. | Polymerizable absorbers of UV and high energy visible light |
US11543683B2 (en) | 2019-08-30 | 2023-01-03 | Johnson & Johnson Vision Care, Inc. | Multifocal contact lens displaying improved vision attributes |
US11958824B2 (en) | 2020-06-11 | 2024-04-16 | Johnson & Johnson Vision Care, Inc. | Photostable mimics of macular pigment |
Also Published As
Publication number | Publication date |
---|---|
AU2004271948A1 (en) | 2005-03-24 |
KR20060076291A (en) | 2006-07-04 |
TW200518724A (en) | 2005-06-16 |
CA2536730A1 (en) | 2005-03-24 |
JP2007504855A (en) | 2007-03-08 |
EP1663334A1 (en) | 2006-06-07 |
WO2005025632A1 (en) | 2005-03-24 |
CN1849146A (en) | 2006-10-18 |
US20060020340A1 (en) | 2006-01-26 |
US20060020337A1 (en) | 2006-01-26 |
US7241312B2 (en) | 2007-07-10 |
US20060020338A1 (en) | 2006-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7241312B2 (en) | Silicone intraocular lens with blue light absorption properties | |
US7304117B2 (en) | Reactive yellow dyes useful for ocular devices | |
US7276544B2 (en) | Process for manufacturing intraocular lenses with blue light absorption characteristics | |
US7033391B2 (en) | High refractive index silicone-containing prepolymers with blue light absorption capability | |
US7198639B2 (en) | Polysilsesquioxane containing polymeric compositions | |
AU2003243507B2 (en) | Low water content high refractive index, flexible, polymeric compositions | |
US6918931B2 (en) | Prepolymers with yellow dye moiety | |
US7659325B2 (en) | Functionalized dyes and use thereof in ophthalmic lens material |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BAUSCH & LOMB INCORPORATED, NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LAI, YU-CHIN;RUSCIO, DOMINIC V.;REEL/FRAME:014309/0656;SIGNING DATES FROM 20031121 TO 20031124 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |